Comparison
Alpha-GPC vs CJC-1295
Side-by-side of Alpha-GPC and CJC-1295. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-GPC
Alpha GPC supplement profile: 300 to 600 mg dosage, acetylcholine synthesis, attention and reaction-time evidence, side effects, and choline donor comparisons.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Effects at a glance
Alpha-GPC
- •Choline donor supplement, roughly 40% choline by weight; crosses blood-brain barrier efficiently
- •Replicated small gains in attention and reaction time at 300 to 600 mg in healthy adults
- •Standard prescription cognitive medication in much of Europe (Gliatilin) at 1,200 mg/day for vascular cognitive impairment
- •ASCOMALVA trial (n=210) showed cognitive preservation when added to donepezil over 24 months
- •Increases acute power output (~14%, single trial) and transient growth hormone secretion at 600 mg
- •TMAO production raises a contested cardiovascular concern at chronic high doses
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Side-by-side
| Attribute | Alpha-GPC | CJC-1295 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | L-Alpha glycerylphosphorylcholine, choline alfoscerate, GPC, alpha-glyceryl phosphorylcholine | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog |
| Half-life (hr) ↗ | 4 | 168 |
| Typical dose (mg) ↗ | 600 | 0.1 |
| Dosing frequency | 1 to 3 times daily | weekly (DAC); 1-3x daily (non-DAC) |
| Routes | oral | subcutaneous |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 3 |
| Molecular weight | 257.22 | 3367.83 |
| Molecular formula | C8H20NO6P | C152H252N44O42 |
| Mechanism | Hydrolyzed to free choline and glycerophosphate after absorption; choline supports acetylcholine and phosphatidylcholine synthesis in CNS. | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. |
| Legal status | Dietary supplement (US); prescription medication in much of Europe | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Insufficient data; choline generally recommended in pregnancy | Insufficient data; not recommended |
| CAS | 28319-77-9 | 446262-90-4 |
| PubChem CID | 71920 | 91971820 |
| Wikidata | Q411478 | Q5012154 |
Safety profile
Alpha-GPC
Common side effects
- mild GI upset
- headache
- dizziness
- occasional insomnia with evening dosing
Contraindications
- established cardiovascular disease (TMAO concern)
- concurrent strong anticholinergic therapy
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors (donepezil): additive cholinergic effect, basis for ASCOMALVA protocol(minor)
- scopolamine: partial counteraction of anticholinergic effect(minor)
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Which Should You Take?
Alpha-GPC comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Alpha-GPC.
- → If your priority is athletic performance, pick Alpha-GPC.
- → If your priority is post-training recovery, pick CJC-1295.
- → If your priority is growth-hormone axis, pick CJC-1295.
Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-GPC is the more accessible choice.
Default choice: Alpha-GPC. Lower friction to source, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-GPC and CJC-1295?
Alpha-GPC and CJC-1295 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-GPC or CJC-1295?
Alpha-GPC half-life is 4 hours; CJC-1295 half-life is 168 hours.
Can you stack Alpha-GPC with CJC-1295?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper